Human Activin A Market is Expected to Reach $15,456.8 Thousand by 2026

ABOUT THIS REPORT

OVERVIEW

Human Activin A Market is expected to reach 15,456.8 thousand US$ by 2026; growing at a CAGR of 12.9% till 2026.

In terms of volume, the Human Activin A Consumption was valued at 949.6 Mg in 2019 witnessing a CAGR of 12.4% from 2020 to 2026.

Activin A is a member of the TGF-β superfamily of cytokines, was originally identified as an inducer of follicle-stimulating hormone release, and it modulates the proliferation and differentiation of various target cells. Activin A is a disulfide-linked homodimer that binds to heteromeric complexes of type I and a type II serine-threonine kinase receptor. Activin A and its binding protein follistatin can be crucial in glucose homeostasis, as multifunctional proteins mediating inflammatory and anti-inflammatory effects. Human Activin A maintains the undifferentiated state of human embryonic stem cells and facilitates differentiation of human embryonic stem cells into definitive endoderm.

The increasing use of human activin A for renal damage in AAV patients is boosting the global human activin A market. According to the researches, measuring the levels of activin A protein in the urine can help clinicians identify patients with renal problems caused by antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Activin A is known to control kidney development and to block regeneration of renal tubules after injury in adult kidneys. Moreover, increasing the use of human activin A in research activities would provide lucrative opportunities for the market in the coming years.

IL-4, GM-CSF, and Others in the type segment of the market scope, the application segment is further divided into Commercial Research and Academic Research, and the end-user segment is categorized into Duloxetine HCl and Others. The report covers the value of the global market by type, application, and end-user.

The market value IL-4 was XX thousand US$ in 2019, and it is expected to reach XX thousand US$ by 2026, growing at a CAGR of XX during 2020-2026. IL-4 is the dominant segment and accounted for approximately 47.59% of the market in 2019, due to the increase in clinical trials of IL-4 vaccine for the treatment of autoimmune diseases.

North America, Europe, Asia Pacific, South America, and Middle East & Africa are taken into consideration at the global human activin A Value figures. While North America is further categorized into enhancing the United States, Canada, and Mexico, Europe is split into the United Kingdom, Germany, France, Italy, and Rest of Europe. Asia-Pacific covers India, China, Japan, South Korea, and Rest of Asia Pacific in its scope. South America is bifurcated into Brazil, Argentina, and Rest of South America, with Middle East & Africa involving GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

North America human activin A market was XX thousand US$ in 2019, and it is predicted to reach XX thousand US$ by 2026, growing at a CAGR of XX during the forecast period. The increasing clinical study of human activin A in human blood would improve the growth of the market.

Major players operating in the human activin A industry include Ajinomoto, Thermo Fisher Scientific, Merck, STEMCELL, PeproTech, Bio-Techne, StemRD, Prospec, Proteintech Group, Enzo Biochem, Sino Biological, ReproCELL.

The facility expansion by the companies to develop human activin A, the formation of strategic collaborations and commercialization of products are the few business strategies adopted by the key companies, with a focus on maintaining a competitive advantage over others. The companies are focused on strategic acquisition to solidify their position in the market and expansion of business activities on a global scale.